520 related articles for article (PubMed ID: 18519851)
1. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
Kastelein JJ; van der Steeg WA; Holme I; Gaffney M; Cater NB; Barter P; Deedwania P; Olsson AG; Boekholdt SM; Demicco DA; Szarek M; LaRosa JC; Pedersen TR; Grundy SM; ;
Circulation; 2008 Jun; 117(23):3002-9. PubMed ID: 18519851
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
3. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
4. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
5. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K
Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
Ballantyne CM; Raichlen JS; Cain VA
J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
[TBL] [Abstract][Full Text] [Related]
7. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
Boekholdt SM; Arsenault BJ; Hovingh GK; Mora S; Pedersen TR; Larosa JC; Welch KM; Amarenco P; Demicco DA; Tonkin AM; Sullivan DR; Kirby A; Colhoun HM; Hitman GA; Betteridge DJ; Durrington PN; Clearfield MB; Downs JR; Gotto AM; Ridker PM; Kastelein JJ
Circulation; 2013 Oct; 128(14):1504-12. PubMed ID: 23965489
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
Ingelsson E; Schaefer EJ; Contois JH; McNamara JR; Sullivan L; Keyes MJ; Pencina MJ; Schoonmaker C; Wilson PW; D'Agostino RB; Vasan RS
JAMA; 2007 Aug; 298(7):776-85. PubMed ID: 17699011
[TBL] [Abstract][Full Text] [Related]
9. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.
Liem AH; van de Woestijne AP; Roeters van Lennep HW; Zwinderman AH; van der Steeg WA; Jukema JW
Curr Med Res Opin; 2008 Feb; 24(2):359-64. PubMed ID: 18081989
[TBL] [Abstract][Full Text] [Related]
10. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
[TBL] [Abstract][Full Text] [Related]
11. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
12. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.
Ballantyne CM; Andrews TC; Hsia JA; Kramer JH; Shear C;
Am J Cardiol; 2001 Aug; 88(3):265-9. PubMed ID: 11472705
[TBL] [Abstract][Full Text] [Related]
13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
14. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
Boekholdt SM; Arsenault BJ; Mora S; Pedersen TR; LaRosa JC; Nestel PJ; Simes RJ; Durrington P; Hitman GA; Welch KM; DeMicco DA; Zwinderman AH; Clearfield MB; Downs JR; Tonkin AM; Colhoun HM; Gotto AM; Ridker PM; Kastelein JJ
JAMA; 2012 Mar; 307(12):1302-9. PubMed ID: 22453571
[TBL] [Abstract][Full Text] [Related]
15. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
Robinson JG; Wang S; Jacobson TA
Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895
[TBL] [Abstract][Full Text] [Related]
18. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
19. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
20. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
